Norhashimah Abu Seman1*, Nur Amanena Khairuddin1, Wan Nazaimoon Wan Mohamud1, Harvest F. Gu2
1. Endocrine and Metabolic Unit, Institute for Medical Research, National Institutes of Health Malaysia, Ministry of Health Malaysia, 40170 Shah Alam, Selangor, Malaysia
2. School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 210009 Nanjing, China
*Corresponding author: Norhashimah Abu Seman.
ABSTRACT
INTRODUCTION: Chronic inflammation is a key factor in the pathogenesis and progression of diabetic nephropathy (DN), a major microvascular complication of diabetes mellitus (DM). Elevated circulating levels of inflammatory markers, pentraxin 3 (PTX3), have been observed in patients with DN and are associated with worsening renal function.
OBJECTIVE(S): This study aimed to determine the association of genetic polymorphisms in the PTX3 gene on inflammation markers among diabetic patients with end-stage renal disease (ESRD).
MATERIALS & METHODS: The rs2305619 of intron 1 and rs3816527 of exon 2 in PTX3 gene were analysed. These variants were genotyped in diabetic patients with ESRD (n = 303) and normal glucose tolerance (NGT) subjects (n = 562) using polymerase chain reaction (PCR). The genetic variants were correlated with plasma PTX3 using a commercial sandwich enzyme-linked immunosorbent assay (ELISA) kit (Quantikine Human; R&D Systems Inc., Minneapolis, USA).
RESULTS: The distribution of PTX3 genotypes and alleles was concordant between DN patients and NGT subjects. There is a significant difference between DN patients with ESRD who carry the AA allele of the PTX3 gene compared to NGT (p < 0.01). Both the AA genotype of PTX3 rs2305619 and rs3816527 SNPs were linked to higher levels of PTX3 (5.8 ng/ml vs 14.0 ng/ml; p < 0.01) in DN patients with ESRD when compared to NGT subjects.
CONCLUSION: The PTX3 rs2305619 and rs3816527 polymorphisms appear to influence the inflammatory profile in diabetic patients with ESRD. These results highlight the potential clinical significance of these variants as biomarkers for disease progression and therapeutic targets, supporting the role of genetic factors in regulating inflammation in DN.
KEYWORDS: Pentraxin 3, Diabetic Nephropathy, Single Nucleotide Polymorphisms, Inflammation


